[Pharmacological investigation of bezafibrate, a hypolipidemic agent (1). Effects of bezafibrate on normal and experimental hyperlipidemia in rats].

Abstract

The hypolipidemic effects of bezafibrate were examined in normal rats and an experimentally induced hyperlipidemic model of rats. Oral administration of bezafibrate at 1 mg/kg/day or more to normal rats for 7 days significantly decreased serum triglyceride (TG) and at 3 mg/kg/day or more for 7 days caused significant reduction of serum total cholesterol (TC). A single oral dose of 100 mg/kg of bezafibrate significantly inhibited the increase of serum TC and TG in hyperlipidemic rats induced by Triton WR-1339. When normal rats were given 75% fructose solution for 7 days, serum TG increased in concentration about four times. Oral administration of bezafibrate for 7 days at 1 mg/kg/day or more inhibited the increase of serum TG in this model. Serum TC increased in concentration about twice in 1% cholesterol diet-fed rats for 8 weeks. Oral administration of bezafibrate at 30 mg/kg/day or more inhibited the increase of serum TC. These results suggest that bezafibrate is effective in the treatment of hyperlipidemia.

• Authors: H Kusama, M Nishiyama, S Ikeda
• Journal: Nihon yakurigaku zasshi. Folia pharmacologica Japonica (Nihon Yakurigaku Zasshi) Vol. 92 Issue 3 Pg. 175-80 (Sep 1988) ISSN: 0015-5691 [Print] Japan
• PMID: 3243507 (Publication Type: Journal Article)

Chemical References

• Cholesterol, Dietary
• Triglycerides
• Fructose
• Polyethylene Glycols
• tyloxapol
• Bezafibrate

Topics

• Administration, Oral
• Animals
• Bezafibrate (pharmacology, therapeutic use)
• Cholesterol, Dietary
• Depression, Chemical
• Fructose
• Hyperlipidemias (drug therapy)
• Male
• Polyethylene Glycols
• Rats
• Triglycerides (blood)